{"contentid": 488676, "importid": NaN, "name": "Chugai launches Polivy intravenous infusion for diffuse large B-cell lymphoma", "introduction": "The Roche  unit Chugai has announced the launch of Polivy (polatuzumab vedotin) intravenous infusion 30mg and 140mg for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in Japan.", "content": "<p>The Roche (ROG: SIX) majority-owned Japanese drugmaker Chugai (TYO: 4535) has announced the launch of Polivy (polatuzumab vedotin) intravenous infusion 30mg and 140mg for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in Japan.</p>\n<p>Polivy, which was&nbsp;developed by Roche using Seagen (Nasdaq: SGEN) technology, had been approved by Japan&rsquo;s Ministry of Health, Labour and Welfare (MHLW) on March 23 and has now been listed on the national health insurance (NHI) reimbursement price list.</p>\n<p>Chugai&rsquo;s president and chief executive Osamu Okuda said: &ldquo;We are very pleased to launch Polivy as a new treatment for relapsed or refractory DLBCL.</p>\n<p>&ldquo;R/R DLBCL represents a high unmet medical need given the limited treatment options. We are committed to providing information in order to promote appropriate use of this first-in-class anti-CD79b antibody-drug conjugate so that we may contribute to better treatment for patients.&rdquo;</p>\n<p>The approval is based on data including the results from a multicenter overseas Phase Ib/II clinical study that tested the efficacy and safety of Polivy in combination with bendamustine and rituximab (BR therapy) compared to BR therapy alone, and a multicenter, single-arm Japanese Phase II study that evaluated Polivy in combination with BR therapy in R/R DLBCL.</p>\n<p>A double-blind, placebo-controlled global Phase III study is ongoing for untreated DLBCL to examine the efficacy and safety of Polivy in combination with rituximab plus cyclophosphamide, doxorubicin, prednisolone compared to rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisolone.</p>\n<p>This product was granted accelerated approval in the USA in June 2019 and conditional marketing authorization in the European Union in January 2020, respectively.</p>", "date": "2021-05-19 16:26:00", "meta_title": NaN, "meta_keywords": "Polivy, DLBCL, treatment, Chugai, infusion, large, B-cell, lymphoma, intravenous, diffuse, Roche, launch, relapsed, refractory, launches, announced, unit", "meta_description": "The Roche (ROG: SIX) unit Chugai has announced the launch of Polivy (polatuzumab vedotin) intravenous infusion 30mg and 140mg for the treatment of relapsed or r", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-19 16:19:01", "updated": "2021-05-19 16:56:57", "access": NaN, "url": "https://www.thepharmaletter.com/article/chugai-launches-polivy-intravenous-infusion-for-diffuse-large-b-cell-lymphoma", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "chugai-large.jpg", "image2id": "chugai-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Hematology, Oncology", "topic_tag": "Asia Pacific, Focus On, Product Launch", "geography_tag": "Japan, Switzerland", "company_tag": "Chugai, Roche, Seagen", "drug_tag": "Polivy", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-19 16:26:00"}